Clinical trials: Dapagliflozin
Dapagliflozin Adverse Reaction, Efficacy
Dapagliflozin in Systemic Right Ventricle (DAPA-SERVE)
The purpose of this study is to describe safety and efficacy of Dapaglifozin in adults patients with a systemic right ventricle (congenitally corrected transposition of the great arteries or transposition of the great arteries…
- Conditions
- Dapagliflozin Adverse Reaction, Efficacy, Systemic Right Ventricle
- Trial name
- DAPA-SERVE (NCT05717257)
- Testing
- Dapagliflozin 10mg Tab
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Monaldi Hospital
Ischemic Cardiomyopathy
RestoratIon of Myocardial Function by PeRcutaneous cOronary interVEntion in Patients With Ischemic CardioMyoPathy
To compare the effects of physiology- and imaging-guided PCI combined with optimal medical therapy (OMT) versus OMT alone on the recovery of left ventricular systolic function in patients with ischemic cardiomyopathy and…
- Trial name
- IMPROVE-ICMP (NCT06930092)
- Testing
- Physiology-and imaging-guided PCI, Optimal medical treatment
- Where
- South Korea
- Volunteers
- 158 people
- Sponsor
- Seoul National University Hospital
Type 2 Diabetes
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
A real-world, nationwide, register-based, randomised trial (RRCT) comparing SGLT2 inhibitors with metformin as standard treatment in early typ 2 diabetes.
- Trial name
- SMARTEST (NCT03982381)
- Testing
- Metformin, Dapagliflozin 10 MG
- Where
- Sweden
- Volunteers
- 2,067 people
- Sponsor
- Uppsala University
Diabetes
A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone
This clincial trial is evaluating if the co-administration of saxagliptin and dapagliflozin, in addition to metformin, results in better glycemic control, as measured by HbA1c, over a treatment period of 52 weeks, compared to the…
- Trial name
- NCT02419612
- Testing
- Saxagliptin, Dapagliflozin, Glimepiride
- Where
- 84 sites in United States, Czechia and 8 more
- Volunteers
- 444 people
- Sponsor
- AstraZeneca
Non-alcoholic Steatohepatitis
Efficacy and Safety of Dapagliflozin in Patients with Non-alcoholic Steatohepatitis
Patients with non-alcoholic fatty liver disease (NAFLD) are at increased risk of more aggressive liver disease; non-alcoholic steatohepatitis (NASH) and at a higher risk of death from cirrhosis, hepatocellular carcinoma and…
- Trial name
- NCT05254626
- Testing
- Dapagliflozin 10Mg Tab, Pioglitazone 30 mg
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Cairo University
Type 1 Diabetes Mellitus
Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes
The purpose of this study is to determine if adding dapagliflozin to insulin is a safe and effective therapy to improve glycemic control in patients with type 1 diabetes.
- Trial name
- DEPICT 2 (NCT02460978)
- Testing
- Dapagliflozin
- Where
- 136 sites in United States, Argentina and 11 more
- Volunteers
- 815 people
- Sponsor
- AstraZeneca
Diabetes Mellitus Type 2
Effect of Dapagliflozin on Microvascular and Macrovascular Circulation and Total Body Sodium Content
Dapagliflozin leads to improved vascular function in the micro- and macrocirculation by action on various cardiovascular risk factors, in particular by effectively controlling hyperglycemia, arterial hypertension and reducing…
- Trial name
- Dapa (NCT02383238)
- Testing
- Dapagliflozin
- Where
- Germany
- Volunteers
- 59 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Diabetes Mellitus, Type 2
A Study to Evaluate the Efficacy and Safety of Dual add-on Therapy With Gemigliptin 50 mg and Dapagliflozin 10 mg Added to Metformin Who Have Inadequate Glycemic Control on Metformin Alone
The objective of this study is to evaluate the efficacy and safety of dual add-on therapy with Gemigliptin 50 mg and Dapagliflozin 10 mg added to Metformin compared to add-on therapy with Gemigliptin 50 mg in combination with…
- Trial name
- NCT04255238
- Testing
- Gemigliptin 50mg, Dapagliflozin 10mg
- Volunteers
- 468 people
- Sponsor
- LG Chem
Type 2 Diabetes Mellitus (T2DM)
Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM
Study D1690L00149 is a 24-week, multicentre, randomized, parallel, interventional, non-inferiority, open-label study designed to compare the FDC Regimen of Dapagliflozin/Metformin XR with the Dapagliflozin co-administered with…
- Trial name
- NCT06327815
- Testing
- Xigduo (Dapagliflozin and Metformin hydrochloride extended-release) tablets, Dapagliflozin tablets and Metformin HCl extended-release tablets
- Where
- 35 sites in China
- Volunteers
- 633 people
- Sponsor
- AstraZeneca
Pediatric Brain Tumor, Pediatric Solid Tumor
Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)
This is a pilot phase Ib study of the safety of dapagliflozin (in addition to standard of care treatment) for the treatment of pediatric patients with recurrent brain tumors and relapsed/refractory solid tumors.
- Trial name
- NCT05521984
- Testing
- Dapagliflozin, Carmustine, Topotecan
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
Administration of the SGLT-2 Inhibitor Dapagliflozin in the Patients With Amyloid Cardiomyopathy
Efficacy and safety of early administration of the SGLT-2 inhibitor dapagliflozin will be evaluated in patients with HF, regardless of LVEF, due to amyloid cardiomyopathy.
- Conditions
- Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Amyloid Cardiomyopathy
- Trial name
- NCT05795400
- Testing
- Dapagliflozin 10mg Tab
- Where
- Russia
- Volunteers
- 50 people
- Sponsor
- National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
AMI, STEMI
DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction
Recent clinical trials have proven the cardiovascular benefits of new medications for patients with heart failure with reduced ejection fraction (HFrEF), especially sodium-glucose co-transporter 2 (SGLT2) inhibitors.
- Conditions
- AMI, STEMI, NSTEMI, Left Ventricular Dysfunction
- Trial name
- DAPAPROTECTOR (NCT05764057)
- Testing
- Dapagliflozin propanediol (FORXIGA™/FARXIGA™1)
- Where
- France
- Volunteers
- 450 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Type 2 Diabetes
Evaluation of Efficacy and Safety of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Diet and Exercise Alone
This study intends to compare the efficacy and safety of dapagliflozin versus placebo in treatment-naïve subjects with type 2 diabetes who have inadequate glycaemic control with diet and exercise alone.
- Trial name
- NCT01257412
- Testing
- Dapagliflozin
- Where
- 15 sites in India
- Volunteers
- 375 people
- Sponsor
- AstraZeneca
Nephrotic Syndrome
SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome
This randomized controlled clinical trial aims to evaluate the efficacy and safety of sodium-glucose cotransporter 2 (SGLT2) inhibitors (dapagliflozin and empagliflozin) in adult patients with primary nephrotic syndrome.
- Trial name
- SGLT2-NS (NCT07214818)
- Testing
- Dapagliflozin, Empagliflozin, Standard Therapy
- Where
- Egypt
- Volunteers
- 75 people
- Sponsor
- Mansoura University
Anterior MI
Impact of DApagliflozin on Cardiac Function Following Anterior Myocardial Infarction in Non-Diabetic Patients
Sodium glucose co-transporter 2 inhibitors (SGLT2i) proved their favorable outcomes in heart failure. However, it is still unknown if their role extent into preventing heart failure, especially after acute myocardial infarction.
- Trial name
- DACAMI (NCT05424315)
- Testing
- Dapagliflozin 10mg, Glucose Tab
- Where
- 2 sites in Egypt
- Volunteers
- 100 people
- Sponsor
- Omar Younis
Acute Heart Failure
Clinical Outcomes of Dapagliflozin in Acute Heart Failure With Reduced Ejection Fraction (CODA-HFrEF)
The goal of this clinical trial is to evaluate the short-term clinical outcomes of starting Dapagliflozin on the same day of hospital admission in patients with acute decompensated heart failure (ADHF) with reduced ejection…
- Trial name
- NCT06012279
- Testing
- Dapagliflozin 10mg Tab
- Where
- 2 sites in Egypt
- Volunteers
- 117 people
- Sponsor
- Cairo University
Diabete Type 2, Non Alcoholic Fatty Liver
Comparative Effects of Aspirin, Metformin and SGLT2 Inhibitors on Liver Enzymes, Lipid Profile, and FibroScan Findings in Non-Alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD), currently referred to as metabolic dysfunction-associated steatotic liver disease (MASLD), is a common hepatic manifestation of metabolic dysfunction and may progress from simple…
- Trial name
- AS-NAFLD (NCT07338331)
- Testing
- Aspirin, Dapagliflozin (10Mg Tab) along with standard medical therapy, Metformin 1000 mg
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Galala University
Type II Diabetes Mellitus
Real World Assessment of Clinical Outcome Changes -Including Month of Ramadan-for Dapagliflozin in Management of Type II Diabetes Mellitus
REWARD is an Non Interventional study aims to describe the changes in the clinical outcomes of Type 2 Diabetes Mellitus patients who are treated with Dapagliflozin for a period of one year including the fasting period of Ramadan
- Trial name
- REWARD (NCT02805361)
- Where
- 4 sites in Kuwait, United Arab Emirates
- Volunteers
- 511 people
- Sponsor
- AstraZeneca
Heart Failure
Real-world Dapagliflozin Treatment in Patients With Heart Failure in Portugal (EVOLUTION-HF)
Heart failure (HF) is a global, public health issue that affects more than 63 million people worldwide; this burden is expected to increase substantially as the population ages.
- Trial name
- EVOLUTION-HF (NCT05465213)
- Where
- 8 sites in Portugal
- Volunteers
- 283 people
- Sponsor
- AstraZeneca
Breast Cancer
Cardiotoxicity in Breast Cancer Patients
The goal of this clinical trial is to learn if dapagliflozin drug has a cardioprotective effect against anthracyclines-induced cardiotoxicity. It will also learn about the safety of dapagliflozin drug.
- Trial name
- NCT06491680
- Testing
- Dapagliflozin 10mg Tab
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Helwan University